Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25031471 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Belen Crespo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department Animal Physiology, Veterinary Medicine School, Complutense University of Madrid (UCM), 28040 Madrid, Spain. Hauptthemen laut MEDLINE: Androgens, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencias, Innovación y Universidades. Instituto de Salud Carlos III..
Abstract (Originalsprache)
The triple-negative breast cancer (TNBC) subtype is characterized by the lack of expression of ERα (estrogen receptor α), PR (progesterone receptor) and no overexpression of HER-2. However, TNBC can express the androgen receptor (AR) or estrogen receptor β (ERβ). Also, TNBC secretes steroid hormones and is influenced by hormonal fluctuations, so the steroid inhibition could exert a beneficial effect in TNBC treatment. The aim of this study was to evaluate the effect of dutasteride, anastrozole and ASP9521 in in vitro processes using human TNBC cell lines. For this, immunofluorescence, sensitivity, proliferation and wound healing assays were performed, and hormone concentrations were studied. Results revealed that all TNBC cell lines expressed AR and ERβ; the ones that expressed them most intensely were more sensitive to antihormonal treatments. All treatments reduced cell viability, highlighting MDA-MB-453 and SUM-159. Indeed, a decrease in androgen levels was observed in these cell lines, which could relate to a reduction in cell viability. In addition, MCF-7 and SUM-159 increased cell migration under treatments, increasing estrogen levels, which could favor cell migration. Thus, antihormonal treatments could be beneficial for TNBC therapies. This study clarifies the importance of steroid hormones in AR and ERβ-positive cell lines of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department Animal Physiology, Veterinary Medicine School, Complutense University of Madrid (UCM), 28040 Madrid, Spain.
- Obstetrics and Gynecology Department, Hospital Clinico San Carlos, Instituto de Salud de la Mujer, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IsISSC), 28040 Madrid, Spain.
- Department of Public and Maternal Child Health University, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain.
- Department of Surgical Pathology, Hospital Clínico San Carlos, 28040 Madrid, Spain.
ORCID-Profile: Belen Crespo, Miriam de la Puente Yagüe, Cristina Diaz Del Arco, Sara Caceres
Förderung
- Ministerio de Ciencias, Innovación y Universidades. Instituto de Salud Carlos III.
Zitieren
APA
Crespo, B., Illera, J. C., Silvan, G., Lopez-Plaza, P., Herrera de la Muela, M., de la Puente Yagüe, M., Diaz Del Arco, C., Illera, M. J., & Caceres, S. (2024). Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25031471
Vancouver
Crespo B, Illera JC, Silvan G, Lopez-Plaza P, Herrera de la Muela M, de la Puente Yagüe M, et al. Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25031471
BibTeX
@article{Crespo2024,
author = {Crespo, Belen and Illera, Juan Carlos and Silvan, Gema and Lopez-Plaza, Paula and Herrera de la Muela, María and de la Puente Yagüe, Miriam and Diaz Del Arco, Cristina and Illera, Maria Jose and Caceres, Sara},
title = {Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25031471}
}
EUVIMED